• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.糖尿病性黄斑水肿患者从雷珠单抗转换为阿柏西普治疗的临床真实世界结果。
Eye (Lond). 2017 Nov;31(11):1629-1630. doi: 10.1038/eye.2017.122. Epub 2017 Jun 16.
2
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.既往抗血管内皮生长因子治疗持续性糖尿病黄斑水肿后改用阿柏西普治疗
Am J Ophthalmol. 2016 Apr;164:118-27.e2. doi: 10.1016/j.ajo.2015.12.030. Epub 2015 Dec 31.
3
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿：DRCR.net方案T的近期临床相关研究结果
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424.
4
Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.阿柏西普、贝伐单抗和雷珠单抗治疗糖尿病性黄斑水肿的比较：数据外推至临床实践
JAMA Ophthalmol. 2016 Jan;134(1):95-9. doi: 10.1001/jamaophthalmol.2015.4110.
5
Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.阿柏西普与雷珠单抗治疗糖尿病性黄斑水肿合并视网膜脱离的比较。
Eur J Ophthalmol. 2020 Mar;30(2):363-369. doi: 10.1177/1120672119827855. Epub 2019 Feb 13.
6
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.阿柏西普治疗对雷珠单抗和/或贝伐单抗反应不完全的糖尿病性黄斑水肿患者的短期疗效
Ophthalmic Surg Lasers Imaging Retina. 2015 Oct;46(9):950-4. doi: 10.3928/23258160-20151008-08.
7
Aflibercept versus ranibizumab for treating persistent diabetic macular oedema.阿柏西普与雷珠单抗治疗持续性糖尿病性黄斑水肿的比较。
Int Ophthalmol. 2015 Aug;35(4):603-9. doi: 10.1007/s10792-015-0081-7. Epub 2015 May 20.
8
Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.评价雷珠单抗和阿柏西普在日常临床实践中治疗糖尿病黄斑水肿的效果。
PLoS One. 2019 Oct 23;14(10):e0223793. doi: 10.1371/journal.pone.0223793. eCollection 2019.
9
Efficacy of Conversion to Aflibercept for Diabetic Macular Edema Previously Refractory to Bevacizumab or Ranibizumab: A Meta-analysis of High-Quality Nonrandomized Studies.对于先前对贝伐单抗或雷珠单抗难治的糖尿病性黄斑水肿，转换为阿柏西普的疗效：高质量非随机研究的荟萃分析。
Ann Pharmacother. 2020 Aug;54(8):750-756. doi: 10.1177/1060028020904358. Epub 2020 Jan 31.
10
Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.2008年至2021年雷珠单抗和阿柏西普玻璃体内注射治疗糖尿病性黄斑水肿的真实世界经验
Acta Ophthalmol. 2024 Jun;102(4):e661-e662. doi: 10.1111/aos.16677. Epub 2024 Mar 25.

引用本文的文献

1
Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema.初始治疗采用阿柏西普后换用法布雷单抗治疗糖尿病性黄斑水肿眼。
Int Ophthalmol. 2024 Jun 25;44(1):275. doi: 10.1007/s10792-024-03226-2.
2
Relationship Between Macular Thickness and Visual Acuity in the Treatment of Diabetic Macular Edema With Anti-VEGF Therapy: Systematic Review.抗VEGF治疗糖尿病性黄斑水肿中黄斑厚度与视力的关系：系统评价
J Vitreoretin Dis. 2022 Nov 18;7(1):57-64. doi: 10.1177/24741264221138722. eCollection 2023 Jan-Feb.
3
Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings.从雷珠单抗转换为阿柏西普治疗后糖尿病性黄斑水肿患者的功能和结构特征。真实世界环境中的三年结果。
Int J Retina Vitreous. 2022 Apr 1;8(1):23. doi: 10.1186/s40942-022-00373-5.
4
Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.持续糖尿病性黄斑水肿患者改用阿柏西普治疗的疗效：一项系统评价与荟萃分析
Ann Transl Med. 2020 Mar;8(6):382. doi: 10.21037/atm.2020.02.04.
5
Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.治疗变更后第 12 个月的结果：SCORE2 研究的二次分析，在继发于中心或半侧视网膜静脉阻塞的黄斑水肿患者中，阿柏西普或贝伐单抗治疗无应答者在第 6 个月时的治疗变更
JAMA Ophthalmol. 2019 Mar 1;137(3):281-287. doi: 10.1001/jamaophthalmol.2018.6111.
6
Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion.视网膜分支静脉阻塞继发黄斑水肿患者从雷珠单抗转换为阿柏西普治疗的真实世界结果
Ophthalmol Ther. 2018 Dec;7(2):387-395. doi: 10.1007/s40123-018-0149-3. Epub 2018 Oct 4.
7
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.阿柏西普治疗具有临床意义的糖尿病性黄斑水肿：日常临床实践中的12个月结果
Clin Ophthalmol. 2018 Jan 8;12:99-104. doi: 10.2147/OPTH.S154421. eCollection 2018.

本文引用的文献

1
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.阿柏西普用于曾接受雷珠单抗和/或贝伐单抗治疗的糖尿病性黄斑水肿眼，可能会进一步改善黄斑厚度。
Ophthalmic Surg Lasers Imaging Retina. 2016 Sep 1;47(9):836-9. doi: 10.3928/23258160-20160901-06.
2
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.阿柏西普治疗对雷珠单抗和/或贝伐单抗反应不完全的糖尿病性黄斑水肿患者的短期疗效
Ophthalmic Surg Lasers Imaging Retina. 2015 Oct;46(9):950-4. doi: 10.3928/23258160-20151008-08.
3
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab.对于对雷珠单抗或贝伐单抗无反应的糖尿病性黄斑水肿，改用阿柏西普治疗。
Clin Ophthalmol. 2015 Sep 16;9:1715-8. doi: 10.2147/OPTH.S81523. eCollection 2015.

Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.

作者信息

Konidaris V E, Tsaousis K T, Al-Hubeshy Z, Pieri K, Deane J, Empeslidis T

机构信息

Ophthalmology Department, Leicester Royal Infirmary, Leicester, UK.

出版信息

Eye (Lond). 2017 Nov;31(11):1629-1630. doi: 10.1038/eye.2017.122. Epub 2017 Jun 16.

DOI:10.1038/eye.2017.122
PMID:28622326
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5684456/
Abstract
摘要